Abivax remains independent despite intense acquisition speculation

Biotech merger activity is at record levels, yet the French company Abivax, which is developing the ulcerative colitis drug obefazimod, has not been bought.

Rumors have floated about a potential $20 billion sale, and the lack of a deal has left investors uneasy.

Without details on any ongoing negotiations, the reasons for the stalled transaction remain speculative, leaving the market to wonder what is holding up a likely acquisition.